← Fady I. Malik

Papers by Fady I. Malik

Page 2 · newest first

51. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Journal of Cardiac Failure · 2024
52. Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in RatsJournal of Medicinal Chemistry · 2024
53. Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathyThe Journal of General Physiology · 2024
54. Exercise Capacity in Patients With Obstructive Hypertrophic CardiomyopathyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
55. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFJournal of Cardiac Failure · 2023
56. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2023
57. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Journal of Cardiac Failure · 2023
58. Novel Potential Targets for Function-Promoting Therapies: Orphan Nuclear Receptors, Anti-inflammatory Drugs, Troponin Activators, Mas Receptor Agonists, and Urolithin AThe Journals of Gerontology Series A · 2023
59. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2023
60. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection FractionENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
61. Efficacy of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide Level: Insights from the GALACTIC-HF TrialEuropean Journal of Heart Failure · 2023
62. Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathyScientific Reports · 2023
63. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2023
64. Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machineryStem Cell Reports · 2022
65. Pharmacokinetics of a single dose of Aficamten ( CK ‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat modelJournal of Veterinary Pharmacology and Therapeutics · 2022
66. A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy ParticipantsJACC Basic to Translational Science · 2022
67. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection FractionJAMA · 2022
68. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
69. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
70. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart FailureENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2021
71. Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle FunctionJournal of Medicinal Chemistry · 2021
72. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic CardiomyopathyJournal of Medicinal Chemistry · 2021
73. Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2021
74. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug‐Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open‐Label Studies in Healthy SubjectsClinical Pharmacology in Drug Development · 2021
75. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJournal of the American College of Cardiology · 2021
76. Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy miceHuman Molecular Genetics · 2021
77. Noninvasive ventilation use by patients enrolled in VITALITY-ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2021
78. Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calciumJournal of Clinical Investigation · 2021
79. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyNeurotherapeutics · 2021
80. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart FailureNew England Journal of Medicine · 2020
81. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart FailureENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2020
82. Left ventricular systolic ejection time is an independent predictor of all‐cause mortality in heart failure with reduced ejection fractionEuropean Journal of Heart Failure · 2020
83. Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison with Contemporary Clinical TrialsEuropean Journal of Heart Failure · 2020
84. Fast skeletal muscle troponin activator CK‐2066260 mitigates skeletal muscle weakness independently of the underlying causeJournal of Cachexia Sarcopenia and Muscle · 2020
85. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection FractionENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2020
86. Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtivInternational Journal of Molecular Sciences · 2019
87. Fast skeletal muscle troponin activator CK‐2066260 increases fatigue resistance by reducing the energetic cost of muscle contractionThe Journal of Physiology · 2019
88. Discovery of Tirasemtiv , the First Direct Fast Skeletal Muscle Troponin ActivatorACS Medicinal Chemistry Letters · 2018
89. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristicsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2018
90. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral SclerosisJAMA Neurology · 2017
91. CK‐2127107 amplifies skeletal muscle response to nerve activation in humansMuscle & Nerve · 2017
92. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbilSHILAP Revista de lepidopterología · 2017
93. New Medicinal Products for Chronic Heart Failure: Advances in Clinical Trial Design and Efficacy AssessmentEuropean Journal of Heart Failure · 2017
94. The Ca²⁺ sensitizer CK‐2066260 increases myofibrillar Ca²⁺ sensitivity and submaximal force selectively in fast skeletal muscleThe Journal of Physiology · 2016
95. Highly selective inhibition of myosin motors provides the basis of potential therapeutic applicationProceedings of the National Academy of Sciences · 2016
96. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertensionAJP Lung Cellular and Molecular Physiology · 2016
97. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart FailureJournal of the American College of Cardiology · 2016
98. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsInternational Journal of Clinical Pharmacology and Therapeutics · 2015
99. Population pharmacokinetic‐pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failureThe Journal of Clinical Pharmacology · 2015
100. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia GravisNeurotherapeutics · 2015